Astra finished 2021 on a strong note, driven by a solid contribution from oncology, diabetes drug Farxiga, the Alexion acquisition and COVID-19 vaccine sales. Although, profitability has again come under pressure, it isn’t a major worry, and should recover as its ‘young’ portfolio matures over time. Although, the recent clamp-down on Chinese entities/drugs by the US is worrisome, and should be watched closely, given Astra’s sizeable Chinese exposure. Overall, these are decent results and our pos ....
11 Feb 2022
Strong finish to 2021, despite some underlying concerns
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong finish to 2021, despite some underlying concerns
AstraZeneca PLC (AZN:LON) | 11,974 74478.3 5.5% | Mkt Cap: 185,625m
- Published:
11 Feb 2022 -
Author:
Amandeep Goyal -
Pages:
6
Astra finished 2021 on a strong note, driven by a solid contribution from oncology, diabetes drug Farxiga, the Alexion acquisition and COVID-19 vaccine sales. Although, profitability has again come under pressure, it isn’t a major worry, and should recover as its ‘young’ portfolio matures over time. Although, the recent clamp-down on Chinese entities/drugs by the US is worrisome, and should be watched closely, given Astra’s sizeable Chinese exposure. Overall, these are decent results and our pos ....